Home › Compound Library › Aniracetam

Aniracetam

Racetamoral · inferred

Lipophilic racetam with anxiolytic properties. Rapidly metabolised (bioavailability ~0.2%) to N-anisoyl-GABA (70-80%) and p-anisic acid. Modulates AMPA receptors, enhances cholinergic/dopaminergic transmission, and reduces anxiety via metabotropic glutamate receptor modulation.

Projected serum levels — 750 mg, twice daily

Aniracetam
Aniracetam modeled serum levels, 750 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 750 mg twice daily (oral).

Modeled steady state after ~1 days: peak ≈ 1.3 mg, trough ≈ 0.10 mg body load. Population-based estimate over 15 days for a 750 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Racetam
Route modeled
Oral
Model confidence
inferred
Half-life
2.9 h
Common dose
750 mg
Suggested maximum
1.5k mg/day
Reference dose range
375–1.5k mg (single dose)
Suggested cadence
twice daily

Research behind this entry

  1. Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study Koliaki CC et al. · CNS Neuroscience & Therapeutics, 2012 DOI

    Prospective open-label study of 276 patients with cognitive disorders found that aniracetam maintained cognitive parameters at 6-12 months and significantly improved emotional state at 3 months.

  2. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries Nakamura K · CNS Drug Reviews, 2002 DOI

    Review of aniracetam pharmacology, metabolites, and preclinical models, including AMPA modulation and cholinergic effects. The author explicitly noted that promising animal findings did not establish clinical efficacy…

  3. Human pharmacokinetics of aniracetam Ogiso T et al. · Clinical Drug Investigation, 1998 DOI

    Characterised aniracetam pharmacokinetics in humans: rapid complete absorption, very low bioavailability (~0.2%), elimination half-life of ~0.5 hours, and extensive first-pass metabolism to active metabolites.

  4. Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers. Tian Y, Zhang JJ, Feng SD, Zhang ZJ, Chen Y · Arzneimittel-Forschung, 2008 DOI

    This citation reports a human clinical study involving Aniracetam. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

4 published studies referenced in the app, each with a plain-language summary.